Series B · Biotech · Basel, Switzerland · Founded 2024 · 11–50 employees
Windward Bio is a clinical-stage biotechnology company developing ultra-long-acting and long-acting biologics to treat serious immunological conditions. The company's lead candidate, WIN378, is an ultra-long-acting anti-TSLP monoclonal antibody designed for twice-yearly dosing. WIN378 is currently undergoing Phase 2/3 clinical testing for asthma and Phase 2 trials for COPD. Windward Bio is also evaluating WIN027, a long-acting anti-TSLP/IL-13 bispecific antibody, in Phase 1 trials. The firm secured a major $165 million crossover financing round in May 2026, bringing its total cumulative equity funding to $365 million.
No open roles listed right now.